Parasite Immunology

Cover image for Vol. 39 Issue 7

Edited By: Eleanor M. Riley and Richard K. Grencis

Impact Factor: 2.493

ISI Journal Citation Reports © Ranking: 2016: 15/36 (Parasitology); 97/150 (Immunology)

Online ISSN: 1365-3024



Author Guidelines


Contents

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details

1. SUBMISSION

Thank you for your interest in Parasite Immunology. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/pim

The submission system will prompt you to use an ORCID iD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.

Click here for more details on how to use ScholarOne

For help with submissions, please contact: pimedoffice@wiley.com

We look forward to your submission.

2. AIMS AND SCOPE

Parasite Immunology is an international journal devoted to research on all aspects of parasite immunology in human and animal hosts. Emphasis has been placed on how hosts control parasites, and the immunopathological reactions which take place in the course of parasitic infections. The Journal welcomes original work on all parasites, particularly human parasitology, helminths, protozoa and ectoparasites. The global readership includes research workers, university and college lecturers and clinicians.

Each issue will contain original papers, brief definitive reports and review articles.

Keywords: parasite immunology, bacteriology, cellular immunology, fungal infection, helminthic disease, immunology, immunopathology, parasites, parasitology, protozoan disease.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

• Original Papers –reports of new research findings or conceptual analyses that make a significant contribution to knowledge (3500 word limit).
• Reviews – critical reviews of the literature, including systematic reviews and meta-analyses (5000 word limit).
• Commissioned Review or Article – by invitation only
• Brief Definitive Reports- preliminary findings of research in progress or a case report of particular interest (1500 word limit).
• Letters to the Editor–are welcomed (400 word limit).
• Meeting Reports– reports on meetings or parts of meetings concerned with parasite immunology. These reports will be commissioned, but the editors will be pleased to receive reports that might be used

4. PREPARING YOUR SUBMISSION

Parts of the Manuscript
The manuscript should be submitted in separate files: main text file; figures and tables.

Main Text File
The text file should be presented in the following order:
i. Title
ii. A short running title of less than 40 characters
iii. The full names of the authors
iv. The author's institutional affiliations where the work was carried out, with a footnote for the author’s present address if different from where the work was carried out
v. Acknowledgments
vi. Abstract and keywords
vii. Main text
viii. References
ix. Tables (each table complete with title and footnotes)
x. Figure legends
xi. Appendices (if relevant). Figures and supporting information should be supplied as separate files.

Title
The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips).

Authorship
For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in the Editorial Policies and Ethical Considerations section.

Acknowledgments
Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Abstract
The Abstract should be divided into the following sections 'Aims', 'Methods and results' and 'Conclusion'; it should not exceed 200 words.

Keywords
Please provide seven keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at https://www.nlm.nih.gov/mesh/.

Main text Following the abstract, the main section should consist of these sections: Introduction, Materials and Methods, Results, Discussion. Pages should be numbered consecutively in arabic numerals. Please also ensure that the lines in your manuscript are numbered.

References
References should be in Vancouver format and numbered consecutively in order of appearance. In text citations should cite references in consecutive order using Arabic superscript numerals and should be listed numerically in the reference list at the end of the article.
Format references as below, using standard (Medline) abbreviations for journal titles. If more than four authors, include the first three authors followed by et al.
Sample references follow:

Journal article
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book
2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p. Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.

Internet Document
9. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003.

Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Preparing Figures
Although we encourage authors to send us the highest-quality figures possible, for peer-review purposes we are happy to accept a wide variety of formats, sizes, and resolutions.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Colour figures
Figures submitted in colour may be reproduced in colour online free of charge.

Appendices
Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Supporting Information
Supporting information is information that is not essential to the article but that provides greater depth and background. It is hosted online, and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information. Note, if data, scripts or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points
The following links provide general advice on formatting and style.
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at http://www.bipm.fr for more information about SI units.

• Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).

• Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

• Human and Murine Genes: For human genes, use genetic notation and symbols approved by the HUGO Nomenclature Committee. Approved gene symbols should be obtained prior to submission from the HUGO Nomenclature Committee, nome@galton.ucl.ac.uk. For nomenclature guidelines, see White et al., 'Guidelines for Human Gene Nomenclature' [Genomics, 45, 468-471 (1997)]. The Gene Name Proposal form may be completed on the Nomenclature Web page: http://www.genenames.org. Use ISCN nomenclature for cytogenetics notation [Mitelman, F. (ed.) ISCN 1995: An International System for Human Cytogenetic Nomenclature, S. Karger, Basel]. Human gene names and loci should be written in uppercase italics and Arabic numerals. Protein products are not italicized. For mouse strain and genetic nomenclature, refer to the International Committee on Standardized Genetic Nomenclature for Mice: http://www.informatics.jax.org/nomen/. New symbols and names for genes should be obtained prior to submission through the online symbol registry form at: http://www.informatics.jax.org/nomen/nomen_submit_form.shtml.

• Microarray Databases:
Parasite Immunology supports the efforts of the Microarray Gene Expression Data Society to standardize the presentation of microarray data, and we recommend that authors follow their guidelines and checklist (http://fged.org/projects/miame/). In addition, the journal strongly recommends the supplemental microarray data be deposited in a public database such as Gene Expression Omnibus (or GEO, at http://www.ncbi.hlm.nih.gov/geo/) or Array Express (http://www.ebi.ac.uk/arrayexpress/) or submitted for peer-review with the initial submission of the manuscript.

Wiley Author Resources
Manuscript Preparation Tips
Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation and Formatting Support
Wiley Editing Services can greatly improve the chances of your manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting and figure preparation, Wiley Editing Services ensures that your manuscript is ready for submission.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editors-in-Chief determine that the paper meets the appropriate quality and relevance requirements. Wiley's policy on confidentiality of the review process is available here.

Data storage and documentation
Parasite Immunology encourages data sharing wherever possible, unless this is prevented by ethical, privacy or confidentiality matters. Authors publishing in the journal are therefore encouraged to make their data, scripts and other artefacts used to generate the analyses presented in the paper available via a publicly available data repository, however this is not mandatory. If the study includes original data, at least one author must confirm that he or she had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

MEDLINE
MEDLINE evaluates a journal's ethical policy by checking that journals ask submitting authors to provide three things: a declaration of conflict of interest (CoI), confirmation that informed consent was sought from test subjects, and that animal rights were taken into consideration. The reviewer will then check three things during the review:

1. Policy Exists: is there evidence in the author guidelines that the journal requires that the appropriate ethical requirements are followed.
2. Policy is Adequate: is the policy appropriate for the journal, e.g. a review journal does not need to have a statement on human/animal rights or informed consent.
3. Policy Consistently Followed: is there evidence in all the published articles that authors have declared their conflicts of interest, and that appropriate procedures were followed when the research was conducted. This will be checked in the final published articles.
We recommend that all articles include a statement regarding COI, regardless of whether or not a COI exists – for example “The authors have stated explicitly that there are no conflicts of interest in connection with this article.”

There should be robust journal workflows in place to ensure all three criteria are met. Examples of failures would be: a journal that requires authors to declare that institutional review board (IRB) approval was sought for their research, but this is not communicated to the readers of the final article; journals that do require declarations of informed consent, but don't say so in the author guidelines; or journals that only publish statements when conflicts-of-interest were declared, and assume that all readers know omission means that there aren't any conflicts.

Human Studies and Subjects
For manuscripts reporting medical studies involving human participants, we require a statement identifying the ethics committee that approved the study, and that the study conforms to recognized standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.
Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher, however in signing the author license to publish authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:
• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration
We require that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.

Research Reporting Guidelines
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. We expect authors to adhere to the ARRIVE guidelines for research reporting standards.

Species Names
Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, the scientific name should be used only.

Genetic Nomenclature
Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see http://varnomen.hgvs.org/, where examples of acceptable nomenclature are provided

Sequence Data
Display of Sequences Prepare sequences as figures, not tables. This will ensure that proper alignment is preserved.

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:
• DNA Data Bank of Japan (DDBJ) www.ddbj.nig.ac.jp
• EMBL Nucleotide Archive: ebi.ac.uk/ena
• GenBank www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories.
• Protein Information Resource (PIR): pir.georgetown.edu
• SWISS-PROT: expasy.ch/sprot/sprot-top

Distribution of Reagents
The Editors of Parasite Immunology have adopted the policy that any readily renewable resources mentioned in a journal article not already obtainable from commercial sources shall be made available to all qualified investigators in the field. The policy stems from the long-standing scientific principle that authenticity requires reproducibility. Publication in Parasite Immunology constitutes a de facto acceptance of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and genomic clones, cell lines, and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro work reported) of novel protein reagents are also considered easily transferable.
Although the Editors appreciate that many of the reagents mentioned in Parasite Immunology are proprietary or unique, neither condition is considered adequate grounds for deviation from this policy. Suitable material transfer agreements can be drawn up between the provider and requester, but if a reasonable request is turned down and submitted to the Editors, the corresponding author will be held accountable. The consequence for noncompliance is simple: the corresponding author will not publish in Parasite Immunology for the following three years.

Conflict of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Funding
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: http://www.crossref.org/fundingdata/registry.html

Authorship
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional authorship options
Joint first or senior authorship: In the case of joint first authorship a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

ORCID
As part of our commitment to supporting authors at every step of the publishing process, Parasite Immunology requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information.

Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at https://authorservices.wiley.com/ethics-guidelines/index.html

Immunity, Inflammation and Disease
Parasite Immunology collaborates with Wiley’s open access journal Immunity, Inflammation and Disease to enable rapid publication of valid research that we are unable to accept for publication in Parasite Immunology. Authors will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Immunity, Inflammation and Disease. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Immunity, Inflammation and Disease will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Immunity, Inflammation and Disease is a Wiley Open Access journal and article publication fees apply. For more information please go to www.immunityinflammationdisease.com.

6. AUTHOR LICENSING

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.
Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons License.
General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under OnlineOpen, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click here.)


Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production
When your accepted article is received by Wiley’s production team, you (corresponding author) will receive an email asking you to login or register with Author Services. You will be asked to sign a publication license at this point.

Accepted Articles
The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After publication of the final version article (the article of record), the DOI remains valid and can continue to be used to cite and access the article.
Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is correct for indexing. Subsequently the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will automatically be updated.

Proofs
Once your paper is typeset you will receive an email notification of the URL from where to download a PDF typeset page proof, associated forms and full instructions on how to correct and return the file.
Please note that you are responsible for all statements made in your work, including changes made during the editorial process and thus you must check your proofs carefully. Note that proofs should be returned 48 hours from receipt of first proof.

Early View
The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before your article appears online, as Editors also need to review proofs. Once your article is published on Early View no further changes to your article are possible. Your Early View article is fully citable and carries an online publication date and DOI for citations.

8. POST PUBLICATION

Access and sharing
When your article is published online:
• You receive an email alert (if requested).
• You can share a link to your published article through social media.
• As the author, you will have free access to your paper (after accepting the Terms & Conditions of use, you can view your article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to your article. You can now order print copies of your article (instructions are sent at proofing stage or use the below contact details).
Email offprint@cosprinters.com
Now is the time to start promoting your article. Find out how to do that here.

Measuring the Impact of your Work
Wiley also helps you measure the impact of your research through our specialist partnerships with Kudos and Altmetric.

9. EDITORIAL OFFICE CONTACT DETAILS

For queries about submissions, please contact pimedoffice@wiley.com

Author Guidelines Updated 7th March 2017


SEARCH

SEARCH BY CITATION